Lipidomic Analysis Reveals Alterations in Hepatic Fatty Acid (FA) Profile Associated With MASLD Stage in Patients With Obesity
Authors' conclusion
Alterations in hepatic FA levels in MASLD patients were due to enhancement of de novo lipogenesis in the liver.
Study context
- Population
- Patients with obesity undergoing bariatric surgery at a university hospital, January 2020–December 2021
- Participants
- 26 / 33 / 32
- Comparison
- No MASLD vs steatotic liver disease vs MASH
- No MASLDn = 26reference
- Steatotic liver diseasen = 33
- MASHn = 32
- Outcome
- Hepatic and serum FA composition by MASLD stage, and relationship with FA dietary intake and MASLD-related risk factors
Methodological detailssingle-centre, Hepatic and serum FA by gas chromatography-mass spectrometry; diet by validated food frequency questionnaires; gene expression by RT-qPCR
- Single-centre
- Hepatic and serum FA by gas chromatography-mass spectrometry; diet by validated food frequency questionnaires; gene expression by RT-qPCR
Main finding
As reported in the abstract
Hepatic and serum FA profiles
- Hepatic, but not serum, FA profiles significantly altered in MASLD vs no MASLD
- C16:0, C18:1 and C18:1/C18:0 ratio higher, C18:0 and C18:0/C16:0 ratio lower in MASLD; significantly different between the 3 groups
- Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters
Observational data: associations, not effects.
Further findings
FA intake
- No differences in FA intake between the groups
Hepatic expression of FA metabolism genes
- Upregulated in MASLD
Original publication
Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity. J Clin Endocrinol Metab. Published 13 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →